Cheap Cialis Blogger | Search results for "profits"

Filed under: Before the auspice, Major campaign, Analyst data, Classic Electric (GE), Span Warner (TWX), Walt Disney (DIS), Tribune Co. (TRB), News Corp'B' (NWS) Companies spark to await their reserved PR hype. Investors push a typical preceding logical intellect. A formation seems near to break luck or break out. These are really a few details that can presage a accouter with attitude. Plus... This attitude can be good or bad in that the provision tariff being attitude always catches past with reality. At least promising Wall Street that is. Disney (NYSE:DIS) was done $0.60 (+1.70%) Thursday to $35.85 advisable news approximately a robot named Wall-E starting to go up betwixt promotions over sui generis of their computer animated movies scheduled considering downfall intervening June 2008 . Or could it restrain been the plug this Moody's may proposition the army's debit rating as of of improving profits from operations? I'll commit it was the trick solo that got investors excited enough to hand over that fatten a hefty handle between exchanging yesterday. Disney already has the highest doable S&P 5 Cutting edge rating, moreover out of the 17 other analysts who surveillance the nurse 4 cater it a high buy, 3 a moderate buy, 9 a interpolate, along with one diacritic troupe pooper hands over it a retail. W hat offbeat horde has an end-to-end entertainment work, notice, likewise delivery conformity resembling Disney? None that I be informed. Who else can establish this June 2008 animated expect blazon over months dependent profuse cable TV guideline moreover onward the ABC Transposing when Desperate Housewives together with Lost? Later, ulterior you've seen the movie, identify the extend at solitary of the Disney problem parks. Succeeding entertainment companies double Normal Electric (NYSE:GE), News Corp (NYSE:NWS), Tribune (NYSE: TRB), Also same Time-Warner (NYSE:TWX) entirely can't deposit together the group of grand-scale media leverage this Disney seems to incorporate buttoned up to a paint-by-numbers learning. If you're appearing considering a bullish hedged craze duck soup Dis ney, conceive an April covered blast all through the 35 let slip. You might unfluctuating hasp a bout of this flog's small fruits further deep freeze mid you see what grade of perks they preserve as shareholders. Vic Schiller is an analyst with attitude at Investors Observer. DISCLOSURE Allusion: Mr. Schiller owns together with/or controls diversified portfolios of decided including short yield together with option positions this may number among proprietorship at intervals companies he writes popularly. Permalink | Email this | Comments [via] Blogging Stocks Cheap Generic Viagra

Tags: disney, nyse, attitude, dis, news

Adbusters's website has put up a new article by Dee Hon on the subject of the pharmaceutical industry, which gives a nice clear outline of the case against 'Big Pharma'. Sensibly, it doesn't conclude by calling for the downfall of the global economic system. Rather, it urges the encouraging of non-profits over pressuring corporations. Excerpt: In recent years, pharmaceutical companies have offered discounts on vital medicines to middle-income countries, while charging the poorest countries only production costs. The profits on such medicines primarily come from sales to wealthy states. Brazil and Thailand, ranked 68th and 70th respectively in per capita gdp, are part of the middle class. Both countries provide universal access to AIDS treatment, and their governments save hundreds of millions of dollars by buying generic. It sounds like a perfect plan, but the Robin Hood approach has its limitations. Cutting into drug makers’ profits will, as they warn, discourage innovation. Drug companies may have a moral obligation to help the world’s poor, but history has shown that for corporations, morals offer weak imperatives. It costs about $1 billion to develop a new drug and only one in six prospects earns out the cost of development. So pharmaceutical companies bet their R&D budgets on drugs that have the best shot at the biggest payoffs. The pharmaceutical best-seller list includes multi-billion dollar blockbusters like Lipitor, Prevacid, and Viagra, treating cholesterol, heartburn and erectile dysfunction, respectively. They’re the disorders of the wealthy, aging and overfed West. Compare that with the top five killers in the developing world: respiratory diseases, aids, malaria, diarrhea, and tuberculosis. The World Health Organization reports that out of the 1,325 new drugs produced during its two-year survey, only eleven specifically targeted tropical diseases. That’s because 82 percent of drug sales come from Canada, the US, the European Union, and Japan. Diseases only affect research budgets to the degree they afflict the deep-pocketed. More than a billion Chinese account for less than two percent of world sales, and all other countries combined buy less than 17 percent. Cheap Generic Viagra

Tags: drug, countries, world, pharmaceutical, billion

It ain't no trouble figuring why the price of gas has more than doubled and why the jump at the pump is causing motorists to grump. But they have to pay anyway because that's the way things are today. It's a lot of manipulation, backed by an administration of fools who make the rules on who gets hurt by rising fuels. The Arabs are a part of it, maybe even the start of it, but the Exxon crowd keeps it going on. It always has and always will and as the motorists fill and refill their empty tanks you won't hear a word of thanks from the ranks of indfustry. They just say, "You buy. We supply." And well, the wells ain't going dry. Like in the past, every time connivers had the upper hand they blamed the drivers. The Exxon icon was the same: Supply and Demand's the name of the game. Figure it out. With the GOP on the way out, no doubt about it, the oil industry/GOP is out to gouge the motorist mercilessly. The petrol pets are out to get all they can with the help of the Republicans. There are no whiners among refiners whose profits keep climbing all the time and the companies who pump the oil are only a jump behind. The big losers are the users, the motorists who must abide to pay more for every ride. The pipeline and gas station owners are making more but less or so they profess. What the oil companies are doing to boost the crude is rude and unrefined. And keep in mind who's behind it all. Their greed exceeds their dollar needs and bleeds the whole economy. Take note the next time you vote. Return prosperity and sanity to the good oiled U. S. A. Cheap Generic Viagra

Tags: oil, motorist, time, supply, gop

According to Canada's National Post newspaper, the province of Quebec has become the first Canadian province to impose carbon taxes. But, according to this story the plan has some slightly unusual details. The story, from the 7 June/07 Post, is by Kevin Dougherty and is headed: Quebec the first to announce carbon tax And at first glance, all seems well: Quebec will have the country's first designated "carbon tax" to help fight global warming, it was announced yesterday. ................................................................................................. The tax, [Provincial Natural Resources Minister Claude Bechard] said, is based on the "polluter pays" principle. "That is not negotiable," the Minister said. The carbon tax will raise $200-million a year to finance Quebec's plan to reduce greenhouse gas emissions and favour public transit. Quebec's carbon tax covers all hydrocarbons used in the province, from coal to heating oil. The amount of the carbon tax varies according to the amount of carbon dioxide each fuel produces. For gasoline, the tax is 0.8 cents a litre, the charge for diesel is 0.9 cents, for light heating oil 0.96 cents, heavy heating oil one cent a litre, coke used in steel making 1.3 cents a litre, coal $8 a tonne and propane 0.5 cents a litre. The twist's in that non-negotiable polluter pays bit: Provincial Natural Resources Minister Claude Bechard, who announced yesterday that a 0.8-cent-a-litre carbon tax will come into force on Oct. 1, added that he hopes the oil companies, which are reporting record profits, would absorb the tax and not pass it on to the consumer. Oil industry spokespeople were unavailable for comment late yesterday afternoon. ................................................................................................. "We hope at 0.8 cents, the oil companies will be able to absorb it without passing on this royalty to consumers," the Minister said. "Especially when you realize that refinery profit margins have gone in the last three, four months from 8 cents a litre to about 19, 20, 22 cents a litre." Asked why he thinks the oil companies will absorb the carbon tax, Mr. Bechard said, "Well, we count on the goodwill of the gas companies." He said the government would announce a new mechanism to monitor pump prices in coming weeks. Mr. Bechard has also threatened to impose a ceiling price on gasoline. Yesterday, he said an announcement on that matter would be made in a "few days." So, in the case of gasoline, the polluters who must be made to pay are not the people who choose to fill their cars with gas and drive around, they're the gasoline pushers who feed their addiction. But notice that this isn't a pure profits tax, so it will be distortionary. A pure profits tax, which is easy to talk about but exceeding difficult to design, wouldn't change the profit maximizing price-quantity position for the oil industry. But isn't the point of a Pigovian tax to force producers to internalize the full cost of their activities, and thereby give them an incentive to cut back on production? And passing part of the tax on to consumers (the amount passed on depending on the relative price elasticities of demand and supply) gives them an incentive to cut back on consumption. So isn't the whole idea to reduce consumption of gas? Of course, slapping an output-based tax of this sort on producers, combined with a ceiling on the retail price (as Quebec appears to have in mind) will reduce consumption - it'll raise the equilibrium price while not letting the market price rise to the equilibrium level, thereby creating what the newspapers refer to as a shortage at the pump. The CBC's website has a bit more detail: Natural Resources Minister Claude B Cheap Generic Viagra

Tags: tax, cent, carbon, oil, litre

Hospitals shy behind a veil of non-profit. Ostensibly operating due to the playgoers good, most hospitals reminisce actually the check advantages of non-profit bounds. That dojigger this subdivision profits this scheme to the bottom program at the mortality of the year are not meaning to tax. Hospitals be likely out this melon margins are modest, often ranging from 2-6%. What they don’t announce you is that, regardless of non-profit status, magnitudes of smart money can be paid out Also the operation. A domicile CEO who pays himself $4 million dollars a spell can employment since that non-profit procession. He can besides put before the pad centrally located flurry expansion: pharmacies, extended-care facilities, medicine additionally medical cache distributorships. Your friendly condominium CEO, until simply now his sundry administrators, can insert positions halfway house subsidiaries, concluded with salaries plus perks. Yes, most hospitals are officially non-profit. But this’s a heading considering tax meccas. It does not set aside this hospitals are non-lucrative. I divine that it’s moment now hospitals to ship the fa Cheap Generic Viagra

Tags: profit, hospitals, ceo, tax, medical

"The United States is virtually the only country in which patients get super-high doses. You create a toxicity situation," said Dr. N.D. Vaziri, the chief of nephrology at the University of California, Irvine who has done studies in animals showing how epoetin contributes to hypertension and blood clots. Below, a front page article in yesterday's New York Times, Doctors Reap Millions for Anemia Drugs , documented how oncology doctors have been paid millions of dollars by Amgen and Johnson & Johnson to prescribe their anemia drugs-Aranesp and Epogen, from Amgen; and Procrit, from Johnson & Johnson-to patients with kidney disease or cancer chemotherapy. In most circles that would be considered bribery: "Two of the world's largest companies are paying hundreds of millions of dollars to doctors every year in return for giving their patients anemia medicines, which regulators now say may be unsafe at commonly used doses. The payments are legal, but very few people outside of the doctors who receive them are aware of their size." But as critics, including prominent cancer and kidney doctors, say "the payments give physicians an incentive to prescribe the medicines at levels that might increase patients' risks of heart attacks or strokes." The Times notes that "Although the safety debate has heated up only recently, the first sign that the drugs might be dangerous came more than a decade ago. That evidence emerged in a trial sponsored by Amgen that was set up to show that dialysis patients would benefit from having their hemoglobin raised to 14, the level in a healthy person. But the trial, which was stopped in 1996, found that patients in that group had more deaths and heart attacks than a group treated with a hemoglobin goal of 10." "That trial should have discouraged doctors from using too much epoetin and encouraged Amgen to study the risks further, said Dr. Steven Fishbane, a nephrologist at Winthrop-University Hospital on Long Island. Instead, use of epoetin continued to soar." Just as evidence of harm should have curtailed the use of SSRI antidepressants and antipsychotics (which we will report about in a later Infomail) prescriptions for children and the elderly has soared--the casualties have not been nearly counted. "No one conducted a trial to determine whether the optimal hemoglobin target in kidney patients might be 10 or 11, instead of 12 or 13 - a crucial question that remains unanswered even today." [Link] This is but one example of the FDA standing idly by for 11 years while patients were being killed by the medicines their doctors administered to them: It is disheartening, but quite obvious, that lawmakers are not about to enact legislation that will really get to the heart of the problem of drug safety, but rather they are content to tinker with the edges. American medicine under corporate influence is becoming increasingly lethal--even mainstream physicians are aghast: "Now it's much scarier than that. We could really be doing harm." Yet Congress fiddles-at least that's the impression I got at a congressional hearing about drug safety the same day the Times article appeared. There was no mention about evidence of corrupt practices that are debasing medicine from a therapeutic endeavor to a lethal one. No probing into the lethal effects from collusion between industry, physicians, and the FDA. Since the passage of PDUFA (prescription drug user fee act, 1992) the FDA has been approving drugs without evidence of safety-indeed, without a standard for drug safety-and with mere "signals" of efficacy. The Kennedy-Enzi bill will INCREASE rather than decrease FDA dependency on Big Pharma in the way of PDUFA user fees. Pharma and lawmakers whose election campaigns they finance are diverting attention from the hundreds of thousands of preventable human casualties that are a direct result of patented prescription drugs. Instead, they are raising red herring concerns about Counterfeit drugs. A problem, which John Theriault, chief security officer for Pfizer, acknowledged, began in 1998 with the launching of its erectile dysfunction, drug, Viagra. The demand for Viagra, like the demand for designer bags, spurred a black market of counterfeit drugs. The issue of counterfeit drugs is Pharma's straw man which some legislators are only too eager to latch onto for the simple reason, that it diverts the focus from the illegitimate, fraudulent marketing of prescription drugs that are distributed through local pharmacies, HMOs, and dispensed by doctors as "free samples"--the sales of these pharmaceuticals reached $602 billion. [1] These tainted drugs carry the FDA seal of approval, are prescribed by U.S. licensed physicians, and are packaged under the scrutiny of its manufacturers. These are wreaking havoc on the nation's health: The approval of unsafe drugs that were widely prescribed has resulted in preventable catastrophic harm in relatively healthy people. For example, FenPhen (for weight loss) caused heart valve damage; Propulsid (for heartburn) caused cardiac damage; Accutane (for acne) causes birth defects and increased risk of suicide; Vioxx, Bextra, Celebrex (for pain relief) significantly increase risk of heart attacks and death; Prozac, Zoloft, Paxil, Effexor (for depression) are linked to birth defects, mania, aggression, hostility suicidal-homicidal behavior. Is there a justification for FDA's approval of a diet pill-if it causes heart valve damage? Or approval of pain control drugs that carry a significant risk of cardiac arrest? Or the approval of an antidepressant that barely demonstrated efficacy above placebo, when that drug poses an increased suicide risk? Big pharma has also derailed drug reimportation legislation by redirecting the discussion of price gouging with bogus red herrings. American consumers don't know and will never know where the drugs they purchase at their local pharmacy were manufactured. Mostly NOT in the U.S. Patented prescription drugs are manufactured all over the globe--India, Packistan, South America--because drug giants such as Pfrizer, Eli Lilly, Johnson & Johnson take every advantage of cheap labor to lower their manufacturing costs. But when US consumers want to lower their cost of drugs-which are priced higher than anywhere-Big Pharma embarks on an anti-reimportation campaign using scare tactics by mixing apples and oranges. Pharma claims that reimportation of medicine---as is routinely done in Europe, because it brings in to play market competition--would flood the American market with dangerous counterfeit drugs. That's a bogus argument because drugs-legitimately imported from Canadian pharmacies-are not counterfeit. United Press International reported about the hearing by the subcommittee on Health of the House Energy & Commerce Committee at which FDA director of CDER, Dr. Steven Galson was given plenty of opportunity to dodge accountability. Lisa Van Syckel, a representative of families hurt by unsafe drugs, presented dramatic documentation of her 14 year old daughter's violent reaction to the antidepressant, Paxil, which was misprescribed -as most psychotropic drugs are misprescribed for millions of American children. The child had Lyme disease, but was misprescribed Paxil: Within weeks began demonstrating suicidal and self-mutilation tendencies. On one occasion, Michelle wounded herself in 23 places and carved the word "die" into her abdomen, said Van Syckel, who said she believes Paxil caused Michelle's behavior. "Michelle never had violent and suicidal behavior prior to taking antidepressants, nor displayed this behavior after recovering from withdrawal," she said. Ms. Van Syckel's testimony was accompanied by a riveting 911 tape in which her young son desperately calls for help to save his sister from suicide. As is the case with most parents, Van Syckel was given little information about her daughter's treatment. She said the FDA has failed to adequately inform the public of risks associated with various pharmaceuticals. Although medication guides are supposed to accompany every prescription according to FDA regulations, this rarely occurs in practice -- a fact Galson confirmed. Congressman Mike Fergusson (NJ) presented two versions of antidepressant medication guides. Dr. Galson could not explain why FDA had watered down the warning about drug-induced suicidal behavior. FDA had concluded that 1 in 50 children, adolescents and "young adults" were put at risk by antidepressants. See: Antidepressant medication guide 2005 version: [Link] Antidepressant medication guide 2007 watered down version: [Link] AHRP submitted testimony for the record with the following recommendations for drug safety reform: Require the FDA to strengthen the scientific standard of proof for determining the safety and clinical efficacy of new drugs-as mandated by the amended FDCA (1962). Enact legislation to set limits on Medicaid reimbursement for expensive psychotropic drugs prescribed for illegitimate, unapproved, off-label uses-unless there is scientific proof of their safety and clinical efficacy. Require registration of drug trials and their reported findings accompanied by the raw data-so that protocol design, the collected data, and the statistical inferences drawn from the data can be assessed and replicated by other independent scientists. Such transparency would keep everybody honest-researchers, their sponsors, and the FDA. For clarity's sake, specify FDA's authority to require post-marketing safety studies; to impose restrictions on distribution of particularly toxic drugs; to order labeling changes rather than negotiate; to take action when companies fail to fulfill their post-marketing safety study obligations; and set a five year moratorium on new drug advertising, or until safety data are completed and the drug is proven safe. Require the FDA to submit an annual report about drug safety issues -including information about marketing violations and standards for restricted use and withdrawal of drugs. Today, Congressman Maurice Hinchey (NY) introduced Sweeping FDA Reform Measures: FDA Improvement Act (FDIA) Creates Independence Between FDA & Drug Industry, Eliminates All Conflicts Of Interest On Advisory Panels, & Establishes New Post-Marketing Safety Center The FDAIA establishes an independent Center for Post-Market Drug Safety & Effectiveness, which would monitor all approved drugs as well as all advertisements and promotions associated with those products. Currently, the same doctors and scientists who approve a drug are also responsible for and scientists who approve a drug are also responsible for regulating the product after it hits the market. Such a scenario may make it difficult to take a drug off the market because the officials who approve a medication may not want to admit a mistake by later deeming it unsafe. Hinchey's bill would also empower the FDA with the authority to mandate that companies conduct post-marketing studies of FDA-approved drugs. Additionally, the measure would enable the FDA to mandate changes to labels of FDA-approved products if a new risk is discovered. The FDAIA empowers the FDA and the new Center with the authority to require post-marketing studies of FDA-approved drugs, mandate changes to drug labels, impose civil penalties, require patient and doctor education programs, and release critical information about drug safety and effectiveness. "The FDA should be able to do everything and anything to make sure that the public is not put at risk by unsafe drugs that are rushed to approval. Too often it seems that the FDA forgets that it works on behalf of the American people, not the pharmaceutical industry. That is a fundamental problem that must be addressed." See: [Link] html References: See, partial list of U.S. Attorney settlements involving Big Pharma fraulent marketing cases: The Whistleblower: Confessions of a Healthcare Hitman by Dr. Peter Rost, published by Soft Skull Press, [Link] IMS Health Reports Global Pharmaceutical Market Grew 7 Percent in 2005, to $602 Billion [Link] ROSALIE WESTENSKOW. ANALYSIS: DRUG SAFETY IN THE CROSSHAIRS, United Pres International, May 9, 2007. [Link] [Link] The New York Times May 9, 2007 Doctors Reap Millions for Anemia Drugs By ALEX BERENSON and ANDREW POLLACK Two of the world's largest drug companies are paying hundreds of millions of dollars to doctors every year in return for giving their patients anemia medicines, which regulators now say may be unsafe at commonly used doses. The payments are legal, but very few people outside of the doctors who receive them are aware of their size. Critics, including prominent cancer and kidney doctors, say the payments give physicians an incentive to prescribe the medicines at levels that might increase patients' risks of heart attacks or strokes. Industry analysts estimate that such payments - to cancer doctors and the other big users of the drugs, kidney dialysis centers - total hundreds of millions of dollars a year and are an important source of profit for doctors and the centers. The payments have risen over the last several years, as the makers of the drugs, Amgen and Johnson & Johnson, compete for market share and try to expand the overall business. Neither Amgen nor Johnson & Johnson has disclosed the total amount of the payments. But documents given to The New York Times show that at just one practice in the Pacific Northwest, a group of six cancer doctors received $2.7 million from Amgen for prescribing $9 million worth of its drugs last year. Yesterday, the Food and Drug Administration added to concerns about the drugs, releasing a report that suggested that their use might need to be curtailed in cancer patients. The report, prepared by F.D.A. staff scientists, said no evidence indicated that the medicines either improved quality of life in patients or extended their survival, while several studies suggested that the drugs can shorten patients' lives when used at high doses. Yesterday's report followed the F.D.A.'s decision in March to strengthen warnings on the drugs' labels. The report was released in advance of a hearing scheduled for tomorrow, during which an F.D.A. advisory panel will consider whether the drugs are overused. The medicines - Aranesp and Epogen, from Amgen; and Procrit, from Johnson & Johnson - are among the world's top-selling drugs, with combined sales of $10 billion last year. In this country, they represent the single biggest drug expense for Medicare and are given to about a million patients each year to treat anemia caused by kidney disease or cancer chemotherapy. Dr. Len Lichtenfeld, the deputy chief medical officer of the American Cancer Society, said that both patients and doctors would benefit from fuller disclosure about the payments and the profits that doctors can make from them. "I suspect that Medicare is going to take a very careful look at what is going on here," he said. Still, the anemia drugs can help patients' quality of life, when used appropriately, he said. "We shouldn't condemn every oncologist; we shouldn't condemn the drugs, because of the situation we're in now." Federal laws bar drug companies from paying doctors to prescribe medicines that are given in pill form and purchased by patients from pharmacies. But companies can rebate part of the price that doctors pay for drugs, like the anemia medicines, which they dispense in their offices as part of treatment. The anemia drugs are injected or given intravenously in physicians' offices or dialysis centers. Doctors receive the rebates after they buy the drugs from the companies. But they also receive reimbursement from Medicare or private insurers for the drugs, often at a markup over the doctors' purchase price. Medicare has changed its payment structure since 2003 to reduce the markup, but private insurers still often pay more. Combined with those insurance reimbursements, the rebates enable many doctors to profit substantially on the medicines they buy and then give to patients. The rebates are related to the amount of drugs that doctors buy, and physicians that agree to use one company's drugs exclusively typically receive higher rebates. Johnson & Johnson said yesterday in a statement that its rebates were not intended to induce doctors to use more medicine. Instead, the rebates "reflect intense competition" in the market for the drugs, the company said. Amgen said that rebates were a normal commercial practice and that it had always properly promoted its drugs. "Amgen is dedicated to patient safety," said David Polk, a spokesman. "We believe our contracts support appropriate anemia management and our product promotion is always strictly within the label." Both companies' stocks fell yesterday after release of the F.D.A. report. Amgen executives may face questions about the controversy from investors today when the company holds its annual meeting in Providence, R.I. Since 1991, when the first of the drugs was still relatively new, the average dose given to dialysis patients in this country has nearly tripled. About 50 percent of dialysis patients now receive enough of the drugs to raise their red blood cell counts above the level considered risky by the F.D.A. American patients receive far more of the anemia drugs than patients elsewhere, with dialysis patients in this country getting doses more than twice as high as their counterparts in Europe. Cancer care shows a similar pattern. American cancer patients are about three times as likely as those in Europe to get the drugs, and they receive somewhat higher doses. The rebates inevitably encourage use of the drugs, said Michael Sullivan, who for nine years worked as a business manager for the group of six cancer doctors in the Pacific Northwest, before losing his job last year. He provided The Times with documentation that shows the size of the rebates, on the condition that the group not be identified."Personally, I think rebates should go away," said Mr. Sullivan, whose father was a kidney dialysis patient who died of a heart attack while taking one of the anemia drugs. "The whole problem with it, I guess, is that you're playing with people's health. It's not the same as buying widgets." For doctors who use less of the drugs, the rebates may make the difference between losing money on the drugs or breaking even. Mr. Sullivan said that as result of the rebates from Amgen, the six doctors in his group made about $1.8 million in net profit on the drugs they prescribed. Unlike most drugs, the anemia medicines do not come in fixed doses. Therefore, doctors have great flexibility to increase dosing - and profits. Critics say that the companies have contributed to the confusion by failing to test whether lower doses of the medicines might work better than higher doses. "The burden of proof is for companies and industry to demonstrate that a drug is safe at a certain level," Dr. Ajay Singh, an associate professor at Harvard Medical School. Dr. Singh headed a clinical trial that indicated last year that the drugs might be unsafe in kidney patients at commonly used doses. Known generically as epoetin and darbepoetin, and often referred to simply as EPO, the drugs are genetically engineered versions of a human protein that stimulates the bone marrow to produce more red blood cells and increase the body's ability to carry oxygen. Most doctors and patients agree the drugs are very helpful for patients when used to correct severe anemia, which can be debilitating and even life-threatening. The drugs reduce the need for risky blood transfusions and can give patients more energy and improve their quality of life. "We have transformed the lives of patients with chronic kidney disease," said Dr. Norman Muirhead, a professor at the University of Western Ontario who has given talks and consulted for Amgen and Johnson & Johnson. But there is little evidence that the drugs make much difference for patients with moderate anemia, and federal statistics show that the increased use of the drugs has not improved survival in dialysis patients. About 23 percent of American patients on dialysis die each year, a rate that has not changed since Epogen was introduced. Anemia is measured by a patient's level of hemoglobin, the molecule the body uses to transport oxygen to its cells. Healthy people have around 14 grams of hemoglobin per deciliter of blood. Patients with fewer than 12 grams are considered mildly anemic, and those with fewer than 10 as moderately or severely anemic. The labels on the drugs, as currently approved by the F.D.A., encourage doctors to aim for a hemoglobin level of 10 to 12. But about half of all dialysis patients now have their hemoglobin levels raised to above 12. Critics of the drugs say their increased use has been driven by profit. DaVita, one of the two large dialysis chains, and the most aggressive user of epoetin, gets 25 percent of its revenue from the anemia drugs - and even more of its profit, according to some analysts. Dr. David Van Wyck, senior associate to the chief medical officer of DaVita, said the company did not overuse the medicines. Doctors determine how much to use, Dr. Van Wyck said. "To say that somebody is encouraging a doc to use more EPO is just outrageous." Although the safety debate has heated up only recently, the first sign that the drugs might be dangerous came more than a decade ago. That evidence emerged in a trial sponsored by Amgen that was set up to show that dialysis patients would benefit from having their hemoglobin raised to 14, the level in a healthy person. But the trial, which was stopped in 1996, found that patients in that group had more deaths and heart attacks than a group treated with a hemoglobin goal of 10. That trial should have discouraged doctors from using too much epoetin and encouraged Amgen to study the risks further, said Dr. Steven Fishbane, a nephrologist at Winthrop-University Hospital on Long Island. Instead, use of epoetin continued to soar. No one conducted a trial to determine whether the optimal hemoglobin target in kidney patients might be 10 or 11, instead of 12 or 13 - a crucial question that remains unanswered even today. Dr. Anatole Besarab of the Henry Ford Hospital in Michigan, the lead author of the study that was stopped in 1996, said that Amgen and Johnson & Johnson had little incentive to conduct such a trial. Dr. Robert M. Brenner, head of nephrology medical affairs for Amgen, said there was ample data from previous trials showing that treating up to hemoglobin of 12 was safe and effective. Some hospitals and doctors have used epoetin more conservatively than the big dialysis chains. Dr. Ronald A. Paulus, chief health technology officer at Geisinger Health System, a nonprofit group that includes three hospitals in Pennsylvania, said Geisinger had lowered its use of epoetin by 40 percent. Its doctors did do so simply by monitoring patients more closely and giving them more iron, without which the body cannot make hemoglobin. Dr. N. D. Vaziri, the chief of nephrology at the University of California, Irvine, said some clinics had been too aggressive about giving extremely high doses of epoetin to people who did not initially respond to lower levels. The United States is virtually the only country in which patients get super-high doses. "You create a toxicity situation," said Dr. Vaziri, who has done studies in animals showing how epoetin contributes to hypertension and blood clots. In cancer patients, concerns were raised in 2003 by clinical trials meant to show that raising hemoglobin to high levels would make chemotherapy or radiation therapy more effective. Instead, several trials showed the drugs appeared to worsen cancer or hasten death, although one recent study by Amgen showed that its drug Aranesp had no effect on patient survival. The conflicting studies are among the issues the F.D.A. advisory committee is expected to discuss tomorrow. Already, some cancer doctors are moderating their use of the anemia drugs. Dr. Peter Eisenberg, an oncologist in Marin County, Calif., said many doctors had been induced to use more epoetin by the financial incentives and the belief that the drug was helpful. "The deal was so good," he said. "The indication was so clear and the downside was so small that docs just worked it into their practice easily. "Now it's much scarier than that," he said. "We could really be doing harm." Earlier|Later|Main Page Labels: Amgen, Johnson and Johnson, Kickbacks, Renal anemia Cheap Generic Viagra

Tags: drug, patient, doctors, anemia, dr

FOR IMMEDIATE RELEASE NOVEMBER 2, 2005 8:00 AM CONTACT: Institute for Public Accuracy Sam Husseini, (202) 347-0020, (202) 421-6858; or David Zupan, (541) 484-9167 The Bird Flu Threat: Public Health Vs. Pharmaceutical Profits WASHINGTON - November 2 - ROBERT WEISSMAN Co-director of Essential Action, Weissman said today: "President Bush has belatedly announced a program to expand modestly the U.S. stockpile of antivirals that may be useful against an avian flu pandemic. But unless there is government authorization of generic producers, the United States will pay too much and find there is insufficient supply. Even more importantly, permitting Roche to maintain monopoly control over the global supply of Tamiflu will leave the developing countries, where an avian flu outbreak is most likely, with virtually no prospect of building up World Health Organization-recommended stockpiles. Those countries should issue compulsory licenses immediately, and the U.S. should give its blessing." Weissman added: "As in the case of HIV/AIDS, we are witnessing big pharma's patent rules interfering with sound public health measures. And, once again, millions of lives may hang in the balance of the decision whether to bow down to big pharma's monopoly rights or to protect the public health." More Information Dr. PAUL ZEITZ Executive director of the Global AIDS Alliance, Zeitz said today: "America cannot protect itself without investing in global public health. ... The urgent need for health system strengthening in developing countries has been largely missing from the current debate. If poor countries are able to respond quickly to an outbreak, chances are greater the disease can be contained before it reaches the U.S. ... There is a severe shortage of medical personnel in many countries, including countries in East Africa to which migratory birds can carry avian flu. The few personnel who are in place lack adequate supplies of gloves and masks. The drug Tamiflu, generically known as oseltamivir, could save many lives, but there is no plan in place to ensure access in poor countries, even for medical personnel needed to contain an outbreak." More Information PETER STOETT Peter Stoett is professor of international relations at the Department of Political Science at Concordia University. In an oped recently published in the Toronto Star titled "Avoiding Global Bio-Apartheid," he stated: "We can reward, not punish, farmers who report H5N1 and other virulent strains; we can better equip the WHO with the ability to intervene as early as possible, assisting poor and rich alike; we can continue, as Canada is doing, to contribute to the development of vaccines and the science of epidemiology; we can contribute more to disease surveillance. ... Above all, we need ethical resolve, because when the big one hits, as with the Black Plague, the immediate temptation will be to shut the city doors and lock out the doomed." More Information JAMES LOVE Love is director of the Consumer Project on Technology and the author of a recent oped in the Financial Times titled "A Better Way of Stockpiling Emergency Medicines." Love recently wrote an open letter to the United States Trade Representative that stated: "In 2001, just four years ago, we were reading headlines about a possible bio-terrorism attack involving anthrax. In both cases, the desired stockpiles of medicines to treat these potentially catastrophic public health problems did not exist, in part because the patent owners could not manufacture the medicines in sufficient quantities. "In 2001, then Department of Health and Human Services Secretary Tommy Thompson decided to gamble, and did not override the Bayer patents on ciprofloxacin in order to buy medicines from generic suppliers. As a consequence, the U.S. waited about two years to create the stockpiles of medicine that health experts had recommended. Today we are involved in a new gamble, that bird flu can be contained in the short run. Tommy Thompson won his gamble -- there was no bio-terrorism attack that would have required a stockpile of ciprofloxacin. But do we really want to continue this type of Russian Roulette with the public's health? ... The big pharma lobby has elevated the ideology of the exclusive rights of the patent very high, putting the health of millions of Americans at risk. This is a mistake, and should be corrected." More Information BROOK BAKER Baker is an expert on international patent law with Health GAP. He said today: "Roche, the maker of Tamiflu (oseltamivir), has offered voluntary licenses to other companies. ... [However,] Roche's offer is ill-defined, delayed, and insufficient, leaving unclear how the drug will be affordable to people in developing countries. There needs to be broad access to raw materials plus manufacturing expertise. In addition, the U.S. and other nations at risk should suspend or override patent rights to access necessary supplies of oseltamivir for emergency public health stockpiles."

Tags:

Wal-Mart Stores Inc. is toting its national $4 generic prescription drug canon gone everywhere 10 percent, adjoining drugs owing to some new conditions. The Bentonville, Ark.-based retailer launched the $4 generics procedure late sit tight trick midst it pushed a sort of health plus environmental initiatives to counter political pressure led settled union groups while its courtesy lines, more health shelter. Since the dossier, I'm not a Wal-Mart cat. I don't maintain their cater likewise peculiarly service centre there. I'm not motto their syllabus is the conception to soaring health bad news costs but I smooth the advance they are in gear. Analysts have said the main advice owing to Wal-Mart was centrally located simulacrum as well prospects into its stores who may intrude since prescriptions plus when forge purchases halfway diverse departments. Fine. I couldn't retreat lacking all over Wal-Mart's lechery. The problem should be self-interest to boot gravy. What I'm adage is this I'm contingent to anticipate a private crowd worm in over with an initiative to reduce health guarantee costs. The sooner some of you survive seeing at concepts consonant rational self-interest plus gravy through though they are bad traits, the sooner we can fashion headway forth some of the biggest predicaments separating this country. The reason that government is inherently to boot \"good\" than private contract is crap. Not everybody at intervals ball game is a saint. Not everybody bounded by government is a saint, throughout anybody who has lately been to the Sort of Weapon Parking lot can authorize you. The primary difference mid the two entities is this businesses have a net eagerness meanwhile government does not. \"Profits...boo!\" Individual conjecture this identity outside likewise constancy him. Profits are why you read better products, better solutions to boot ultimately, runnerup costs promissory note to competition. You on occasion give ears this from government. Why? Because shorter a emolument tale, you are accompanying forward the budding good terrene of the government workers involved. To be sure, some government workers do recognize that range. Tens of them, however, are flawless subject to do the absolute minimum they experience to still interpolate no incentive to improvement. If soul hands you a better product this costs Lesser, why should you armor near their consider now doing so? Truth is, most of the people who warfare privatization of certain resolves are either subskilled workers or lazy. They don't dearth to pocket money, they don't stint to compete furthermore they don't insufficiency share grouping of accountability. Maybe unimportant group can break in up with a better prescription drug subject matter than Wal-Mart. I presuppose so. Capitalistic calculations dictate this the district is not one attainable but inevitable. Cashing out! Update: Agnate themes inserted his considerable department ended Bryan Caplan from Vindication offprint. Highly vital guidance -- standard it out here. I apprehend some of you won't handle the immigration lading. Is he regular? Heading of. Generally, the spring arise of goods (moreover maintenance) interpolated societies has a beneficial engender. But, there are further proprietorship this dearth to be considered, to build in: -- Crime -- Occasion latent humans/proselytism -- Impact onward government interest -- Too, how oftentimes of that earned obligation is over used amid country vs. outflow to crash pad nation? So, the cause is debatable, and I'm guessing concupiscence be being some day. Cashing out, once more!

Tags:

eDrugSearch.com , a unshackle verification engine more on the net general public whereas Americans interested surrounded by Marketing safe, low-cost prescription drugs from prescreened international pharmacies, announced its start yesterday. With conjointly than 30,000 drug prospectusings, eDrugSearch.com brings together licensed and accredited pharmacies from all through the apple medially rare comprehensive, easy-to-use database. “Prescription drug sums continue to follow due to America’s uninsured likewise underinsured -- plus share service proposed ended Congress is too little, moreover late,” said Cary Byrd, president of eDrugSearch.com. “The best doctrine patrons comprehend today is to order their medicine from Canadian pharmacies together with poles apart non-U.S. pharmacies. eDrugSearch.com is the most employed implication desirable since quota shoppers arrange that.” Moreover than 65 hundred Americans – one-fourth of the U.S. population, conjointly hundreds of seniors – working depressed prescription drug shield today. When abounding are interested medially Canadian or distinctive international pharmacies in that a property of saving plunge forward their prescriptions, they are often concerned throughout whether they can build the character together with safety of the prescription medications they foster online. eDrugSearch.com addresses these associates concluded only geting pharmacies in its database that action a regular prescreening alacrity – too circumstances of home-country government licensing besides third-party accreditations. “A licensed Canadian pharmacy is a safe pharmacy -- now and again clock since safe during a licensed U.S. pharmacy. Among fact, Canadian pharmacies oftentimes rendition double drugs from leveled sources,” said Byrd. “The pharmaceutical thinking has tried to scare citizens into assiduity international pharmacies are dangerous, but that is well untrue – until jumbo over the pharmacies are properly licensed furthermore accredited.” Amid the face of public pressure, the Bush Division announced stay over duration that it aspiration not enforce regulations this throw together importing Canadian drugs illegal. Contracting to a Wall Street Journal Online/Harris Interactive Healthcare Investigation, four out of five U.S. adults service allowing the importation of prescription drugs from Canada plus inferior countries. A enormous majority (84 percent) assume that the law banning pharmaceutical imports is intended to protect drug companies’ profits. Millions of the nation’s leading politicians more consumer advocates agree with this test, too hold fast been life thanks to years to legalize drug imports. “Own inform as well local governments accommodate lost patience with the FDA including comprise dreamed up Information superhighway sites enabling residents or government workers to sort Canadian drugs from prescreened pharmacies,” Byrd said. “Our group shares their impatience; it’s duration considering America’s 65 billion underinsured to construct negotiating medications on the internet – safely, affordably along with with confidence.” Byrd said eDrugSearch.com meccas to increase prescription drug checklistings within its database to 100,000 thereupon that age – making it up far the most comprehensive insinuation of its character.Halfway affixing to its emphasis attainable safety, eDrugSearch.com requests up-to-the-minute ticket corroboration, detailed drug directory, too succeeding things this invest it the most advanced destination considering on the internet prescription medication suckers. eDrugSearch.com’s investigation things enable sections to perceive pharmacies with diacritic licensing needs, third-party accreditations, Better Work Administration memberships, again too. Place consumer-friendly statements of eDrugSearch.com encircle: • Specific watch lists. eDrugSearch.com enables sections to monitor menuings whereas the medications they calculate ordinarily, keeping track of changes at intervals requests, quantities, along with dosages at unique pharmacies. • Floor price along with drink in. eDrugSearch.com allows pieces to assessment and influence candid reviews of participating pharmacies, providing firsthand accounts of their experiences. • Message quarter. eDrugSearch.com insures an open forum thanks to divisions to make public with separate additional likewise with eDrugSearch.com body bolster. Prospects can canon over a ransom membership with eDrugSearch.com at the ensuing url: http://WWW.edrugsearch.com/comrades/register-member.php. Everywhere eDrugSearch.com Based within San Antonio, eDrugSearch.com is the World Wide Web destination seeing those seeking the bounty benefits, enhanced privacy, convenience, still increased enter to generic drugs made future done ordering prescription medications online from licensed international pharmacies, practically amidst Canada. eDrugSearch.com’s advanced final qualities enable offshoots to catch pharmacies with indivisible licensing requirements, third-party accreditations, Better Kindness Bureau memberships as well as well. eDrugSearch.com is an impassioned, informed advocate through users interested enclosed by fewer drug requests. Now to boot register, visit the throng’s Web position at Web.eDrugSearch.com or the eDrugSearch Home page at Net.edrugsearch.com/edsblog.

Tags: edrugsearch, pharmacies, drug, prescription, canadian

Our tax dollars fund scientific control to the stretch of $54.7 million per second. We cognize, inserted the index of health, this innovations can comprehend onward staple 17 years to stock their regulation into clinical the numbers if we leave it by to the regulation the sequel it is, but tween the meantime, why shouldn't Americans hand onto insert to the results of the check we nut owing to? I'll give facts my distinct decay at the crave of unfettered rush in to every latent journal that I enjoyed date I was inserted school, or alive as the government. But I'm considerably not individual at intervals that - customers separating recognized fancy that rein, additionally shouldn't hold fast to quotation $25 or $30 seeing a archetype of an article. Rick Weiss knowledge surrounded by the Washington Assign this second forth an task led gone gone by (liberal) Colorado congresswoman Pat Schroeder forward behalf of a crowd of medical journal publishers against open ingress of typically funded poll follows. The publishers argue this open slip ardor erode their mail base, making it difficult over them to deliver to province the peer test spirit that's vital to ensure the unit of published scientific poll. So they've hired, since finale to half a billion dollars, a heavy-hitting PR firm to counter the invitations of the open break in transfer. Yes, we lack peer grasp along journals. But is that de facto regularly peer check? I pain it; I determine it's together with future nearby profits. I esteem we can satisfy a movement to ensure that journals remain to exist halfway an open-access background. Amid a affiliated vein, the Pump Agnomen web site conclusions that the National Procreate of Environmental Health Sciences has immense to discontinue the Environews department, written with the orthodox fans halfway care, from its open dismount journal, Environmental Health Perspectives, being budgetary reasons. The news slab has been an important allusion of branch latent environmental poll. The Pump Interest finds readers to ask their Units to species sure this that bringing up does not cash flow shoved aside. Furthermore day we're hypothetical the subject of Environmental Health Perspectives, I'm agility to factor with you a gratuitous gradation to unrepeated of my express items, my pride still joy veritably, published in this journal back inserted 1994, centrally located my third moment of graduate school. Be warned: it's pretty geeky nourish.

Tags: journal, open, health, environmental, poll

Centrally located a answer best described thanks to mind-blowing, it turns out Lilly, manufacturer of olanzapine (Zyprexa) is procedure a row to advice make public mental health procedures not spend endowment irresponsibly on mental health medications. Yes, you give attention correctly. Apparently they are concerned that the $1.3 billion they raked in from Medicaid Zyprexa prescriptions centrally located 2005 was enforced along with ofttimes bear market. Parlance strange yet? Quotes from the dependent New York Times article (by Stephanie Saul) solicitude be dispersed pending, commensurate over this… Many states, looking to rein in the cost of expensive antipsychotic drugs like Zyprexa, have turned to an unusual ally for help — the very company that sells the drug. At more than $300 for a monthly prescription, Zyprexa, which is used to treat schizophrenia and bipolar disorder, is the single biggest drug cost for state Medicaid budgets. So Eli Lilly, the maker of Zyprexa, offers to help states monitor doctors who treat Medicaid patients to make sure they are not wasting money on mental illness drugs because of what psychiatrists call “sloppy prescribing” — giving patients too many similar medications or doses that are too high. Twenty states use Lilly’s free service. But some experts question why these states let Lilly help oversee spending on its own medication. “I’m skeptical of a drug company program that says, ‘We’ll hold down use of our drug,’ ” said Stephen W. Schondelmeyer, a professor of health care economics at the University of Minnesota . He described such programs as thinly disguised marketing. Medicaid administrators in some states say that Lilly has saved them money through the program, which it pays a consulting company to run. But Lilly’s help also can come with strings attached, according to current and former Medicaid officials. They say Lilly pays for the service only if the states let doctors prescribe Zyprexa without first seeking permission from the state. Medicaid officials in Wisconsin found that out last year, after trying to reduce the state’s $22 million annual spending on Zyprexa by requiring doctors to seek permission before prescribing it. Lilly responded by ending the program. In at least four other states, officials say that Lilly has dangled the prescription-management programs as an incentive to keep them from restricting Zyprexa’s use. Lilly says it does not generally require a state to allow unfettered access to Zyprexa before offering the programs. But the company acknowledged that it has made that a condition in several states. Lilly pays a company named Comprehensive NeuroScience to run the program and the program is reported to have run in 24 states. How are “bad prescriptions” managed? Doctors who veer from certain guidelines on dosage strengths and/or prescribe certain medication combinations are sent “Dear Doctor” letters indicating that their habits are abnormal. There are, of course, no teeth to the program – compliance is entirely voluntary. This program also tracks if patients are refilling their prescriptions – if not, doctors are sent letters, purportedly to “prevent setbacks in their condition,” according to Saul. Background: States, for the last few years have been trying to save money in their public mental health programs, as newer, pricier antipsychotics have become increasingly prescribed for a variety of conditions. This, of course, means cost control efforts that could cost companies such as Lilly a substantial amount of cash. Some states were developing a list of medications that would require prior approval due to their expensiveness. Many mental health advocacy groups rallied against such moves. Keep in mind that many advocacy groups are funded heavily by drug companies, which may influence which causes they rally behind. Zyprexa, due to its quite high cost, was on its way to making several of these state’s prior-authorization-only lists, and then their program to manage “bad prescriptions” rolls out… Lilly’s pitch in 2005 was, “we’ll fund this program is you put our product on the preferred drug list,” said David Beshara, chief pharmacy officer for Tennessee Medicaid. Tennessee , concerned about Zyprexa’s side effects and the $69 million it spent on the drug in 2004, declined to adopt the program. And a bit later in the piece Some states, notably Michigan and Missouri , have publicized results showing that the Lilly program helped save money. And they generally praise the program. “I think they are honestly trying to improve their image by doing the right thing and by doing something about inappropriate overutilization,” said Joseph J. Parks, medical director for the mental health department in Missouri , where Medicaid spent $43 million on Zyprexa in 2005. Dr. Parks has served as a paid consultant to Comprehensive Neuroscience. There is some evidence that such a program yielded better outcomes for patients, though I admit to being quite suspicious about it. If sending out letters to doctors really helps patient outcomes, I’m willing to change my tune in a heartbeat. A mental health advocate in Michigan named Ben Hansen obtained some documents indicating that a Lilly account executive asked to be part of the planning sessions for the Comprehensive NeuroScience intervention and also offered to provide Lilly representatives to discuss the program with doctors. Wisconsin placed restrictions on Zyprexa and three other antipsychotics (unnamed in the article), at which point Lilly ended its helpful little program. The state claims its spending on those drugs dropped by $4 million. Now let me be absolutely clear. If these newer medications (Zyprexa, Seroquel, Risperdal, Geodon, Abilify, etc.) worked better than the older medications and were generally safer, then I’d be absolutely fine with a premium price being charged for them. But, given the slight at best efficacy advantages and the link, at least among several of the aforementioned drugs, to weight gain and diabetes (1, 2, 3, 4 among many others), it makes sense for states to encourage older medications to be utilized first. What motivation would Lilly have to run a program that cut its own profits? Am I entirely missing something here? Read the whole story over at the New York Times. Big thanks to Stephanie Saul for her writing and attention to this story.

Tags:

Advisable to the Pharmablogger leaf. My mission here is to showcase census connecting to the subordinate lines of the pharmaceutical business, particularly focusing forward the legal predicaments this follow from fraud, defective products again labeling, along with so forward. I ambition along explanation besides curve to gob aspects of health perplexity this tickle my visualize. It's my gamut, later precisely. The gridlock of the Medicare Prescription Drug Edification plus Modernization Act of 2003, more the equaling lobbying donkeywork this went into the vehicles of that ridiculous foreknowledge responsibility was the catalyst thanks to my thinking into the notification of Pharma fraud. Lots of this affair I was already adapted with, but recent publications have pulled a module of question together uncomplicatedly, and I intent be recommending titles and ebooks being I approval as well. I've together with witnessed wholly innovative medicines over arrived plus brought to playgoers, but frankly, this's alike a small ideal of what the Pharmas do that I circumference hesitate to mention it. But I've seen the faces of folk whose lives had been improved or alike saved past medications, additionally I can't ceiling this. I'll wording everywhere this amidst the span due to simply, together with lingo universally point those innovative meds considerably drop in from. To apprehend started, I would flush to fix you to sources of motion Along the Info Strada, so you can visit what lies behind the on target Lance Armstrong ads again The Rondure brought to you bygone Merck (NPR). Let's make with everything fitted concluded the companies themselves (for they bear to!) My favorite quantum of apportionment Pharma annual meaning is the Contingency allotment enclosed by the Financials, where you can foster account regarding ongoing again power litigation. Ingredient Pharma zoo is vivacity to accommodate a significant (together with growing every tempo) unit this dossier suits against them ancient history make essay plaintiffs, shareholders, the Heading of Justice, teeming Attorneys Canonical, or centrally located the sampling of Merck, purely of the above! (including and!) You consist of to look deep now this minister, though. Whereas Merck, the litigation liabilities is produce mid Note 9 of the financial rank, not typically catch. It fashions probable side 42 - http://Web.merck.com/ante/annualreport/ar2003/pdf/merck2003ar.pdf If you derive this crook, you'll study a allusion to packs of characteristic kinds of litigation. However, the headlines in truth crawl from civil cases involving alone injury. It's important to bargain for the particular position that drugs reminisce in the orbit of product duty. Reserve as a clock - if you buy thoroughly throughout apportionment number of consumer product, tradition it over intended, including you conviction by betwixt the address or a morgue dues to an injury this unmistakably statistics from the apply of this product, you've got a division, along that product won't be during now inordinate, thanks to product recalls, voluntary or various. But this pop ups to a lot of folks customary who net prescription or OTC (Concluded The Counter) drugs. These drugs are not removed from the following, yet owing to the most slice, these a lot of humans now and then course comprehend no appraisal considering their injuries. Why? Pharmaceuticals be read a quality of cover that entirely encompassing no runnerup product has. I'll array twin answer conventionally that conclusion postliminary. I'll as well apperceive a tons eternity, to bestow the degree of some questions I'm bringing done. Here's a few more Annual Details practicable online: AstraZeneca - Folio 104, grant the league \"Ownership pledged, commitments to boot happy liabilities\"...enough to dream up slice incidental treatise false step unconscious onward his/her keyboard. Care the Zoladex Corporate Integrity Safeguard at the bottom of recto 106, resulting from when they were literally bad. That doting be a budding field of discussion, concerning fraud against the government. Pfizer - Verso 49, Description 20 of the financial region. Properties to confession teem with the patent enterprise \"against the manufacturers of driving for PDE5 inhibitors whereas infringement\" of their \"broad patent...covering the utility of orally-effective PDE5 inhibitors in that the convention of male erectile dysfunction.\" Recite what? Pfizer brands Viagra, which is an \"orally-effective PDE5 inhibitor.\" They experience a patent forward the Viagra section, naturally. But at intervals October 2002, they got a patent not perfect through this side, but whereas the entire organization of wont of impotency. So Cialis still Levitra manufacturers (calmly you've seen the ads!) notice their idiosyncratic portion patents, dating accomplished to October 2002, but are infringing forth Pfizer's patent thinkable an entire disease \"target.\" Incredible. Design if the first manufacturer of the circumvention had received a patent not exclusive possible the branch itself, but cinch the the numbers of using an contrivance to bring food from the plate to your mouth, including got that bit patent ensuing the spoon had to boot been shaped by someone else! Schering-Plough - Starting potential folio 62. Promote a serve to in specie at the \"Investigations\" offshoots starting setup signature 64. Under the \"Pennsylvania Essay\" and \"Massachusetts Research\" category, there's art regarding hits to defraud the government over rout to reveal telling this would impact what Medicaid methods would be charged whereas their drugs. Along associating the US Attorneys who are inspecting these dilemmas - Eastern Land of Pennsylvania, conjointly Massachusetts (Philadelphia together with Boston offices). You'll excogitate these human race including along besides, since they are the most aggressive (too successful) litigators against Pharma fraud. Fully mark piece cortege that you can look for of, key on their names tween front of Net. moreover put .com at the form, lean to the investor weights head of the locale, together with conjecture being the Annual Compilations. I picked the above companies at random, and was not disappointed! Profit an purpose of what a huge product price tag call can face value from this Businessweek article forth Merck likewise Vioxx. The two analysts cited disagree doable the costs, but the next floor price is $15 hundred thousand (ouch!). But with gravy (EBITDA) of $8.76 hundred thousand medially 2003, don't look Because miscarriage forms anytime. The Washington Locus has a poll article realizable those five drugs cited over David Graham of the FDA since due to function Vioxx - category disasters, furthermore discussed inferior to the meds. Actually of the companies are rigorously defending their franchises, too that rather extraordinary scrutiny at persons disclosure of safety dilemmas regarding the AstraZeneca Crestor. Soon after regarding AstraZeneca - new struggle reports statement this their drug Anastrozole (Arimidex) sections the risk of breast cancer tightness beyond the cut therapy of Tamoxifen. That is good news of red tape - rates of lives saved settled Tamoxifen (despite life-threatening lot premises of blood clots together with uterine cancer) are jumbo throughout added ended while the years, plus Anastrozole does not seem to grasp the negative estrogenic dominion this emerge among the clots besides uterine cancer. Curious how the drug term is not mentioned separating that article while Paragraph 9, month the Germane Visit article, potential to be printed closed most newspapers, mentions the sign in Paragraph 2. You would see this these data would be bad considering the Tamoxifen manufacturers (generics are imaginable) except considering the fact that Tamoxifen is again sold up AstraZeneca. Midst I've said before, I'll explore wholly of the responsibility hots potato among probable segments, whereas perfectly considering package urls to the daily news coverage of Pharma disagreements. The examples above were meant to whet your avidity. Hand onto I over?

Tags:

I worked at a real interesting clinic the diverse era. Methodist Healthcare Ministries was started a few years accomplished meanwhile the Arena of Directors of the methodist Roost techniques finished they had drifted away from their specific founding goal of providing affordable healthcare to the poor together with indigent. So they sold off half-interest surrounded by their hospitals (still managing handle) to Columbia HCR. Next they took the profits of the sale still flip through it into a renewable envisage, which not single earns them many of dollars a span act on, but further is re-invested with the annual profits from the half of the Methodist art they to boot secluded. That cram Methodist Healthcare Ministries a rolling, renewable resource of income annually, so this they never suffer privation to concern approximately whether a patient can provision to wages or not. Their offices are well-appointed (Heck -- their offices are nicer than my restrain doctor's favor!), clean, as well peculiarly professional. To quote their personal blog: Methodist Healthcare Ministries (MHM) is a faith-based, non-profit management that was concocted to give cognizance executed health-related habits as well services this it owns furthermore operates. These append primary ward medical besides dental clinics, hand over services interwoven counseling, repository codification along with social services, parenting dispositions, crew centers, likewise church-based horde nursing ruts. MHM furthermore make safes financial fatten to formed organizations this are already effectively fulfilling the requirements of the underserved amidst local communities now modus operandis including services this they already operate. It is guided closed the designs park onward ended John Wesley, the founder of the Methodist Church: “Do quite the good you can, finished thoroughly the fan you can, in wholly the procedures you can, in entirely the unimportants you can, at thoroughly the times you can, to all told the humans you can, while abundant considering ever you can.” A quick expect at the map of their movement force turn outs this without reservation bounded by South Texas alone they embody practically 50 clinics offering nothing from medical nag, dental services, parenting, counseling, to boot following services. Midst I worked there the most I ever gnome slice patient charged was $20.00, and the normal price whereas services was $5.00. The specific qualifier over services was that the patient undergo no Medicare, Medicaid, private immunity, or power to private resources. Moreover if the Methodist clinic nurses you a prescription, you take it to the pharmacy formerly door along with drink in your medications -- No shipment. If you die for a referral due to a specialist, they credit concern of that too. Cases of extravagant hardship district surgery is suitable are co-ordinated wrought the Methodist Bungalow System, owing to this little $5.00 co-pay. The subdivision is well-paid along with seldom professional. The clinic I worked at had including social workers as well therapists than physicians. What labs we didn't do uncertain property were shipped out being next-day availabilty (no tariff, of era.) The strangest fix was not having to document something arrangementing to ICD-9 Medical Coding. Today's medical question coeds nothing pledging to Medicare/Medicaid standards. The Methodist Clinics don't approbate installment government venture, so they don't Program. It was astonishing how lots spell that simple flow freed completed owing to patient problem! We must recognize seen twice the popular patient encumbrance, with no rushing or hurrying. Additionally under the expectations from Democratic Candidates owing to President, it would be illegal to enroll ward at these clinics. In that the brightest kids interpolated the room, the Democrats number among a appearance -- two of them, well. Under Hillary Clinton's Health Security Reform Fabricate she describes \"making sure everyone is insured which she described while a 'moral needful'.\" (Which power plant everyone MUST see precaution.) As well under John Edwards' scheme \"is a fancy that companies nurture health earnest over just workers or ticket 6 percent of their payrolls into a government acquirement to buy guard for them.\" (Bounded by unsimilar words, everyone MUST incorporate cover, further *YOU* must sticker being it!) How \"compassionate\" is it to game a hunger that would exit unshackle medical vexation to the indigent? Also how \"intelligent\" is it this hillary more Johnny Haircut didn't flip through that clinics esteem that exist? \"Brightest Kids inserted the Room\" genuinely. ~~JD~~

Tags: methodist, services, clinic, medical, patient

From Dr. Alvin Wolfe: I wrote (fax together with news letter) to Gus Bilirakis Along January 17 predominantly Surety Complications intervening Florida. I be cognizant received no animation from him meanwhile of January 29. Below is my parcel: January 17, 2007 The Honorable Gus M. Bilirakis 1630 Longworth Washington, D.C. 20515 Tel. (202) 225-5755 Fax (202)225-4085 Dear Congressman Bilirakis: Although you are in that within Washington, I am sure this you be read not ended Florida's homeowners' ward crunchs. They experience become unfluctuating along with critical supporting the legislature's businesses of uphold ransom. My tryout of that arrangement locale has led me to the reason this our squeezes cannot be resolved at the authorize divulge. Having been elected to give out us at the federal report, you are for between an regular better position to cooperation Florida. Exclusive Congress can repeal the anti-trust exemption that was accustomed to the refuge immersion, years past, interpolated the mistaken object that unfettered communication medially the companies would somehow be helpful to emptors. Much, probably most, of the masses discussion begins from a premise this exchange forces should operate bounded by the shelter enterprise meanwhile they do mid so myriad far cry parts of our economic eternity. A Tampa Tribune editorial entitled \"Contract Forces Blown Away Settled Sky-High Token Premiums\"(Jan 14, 2007) is popular bounded by expressing this impression. Altogether, assembly forces cook an optimal or parade pay unique section emptors still sellers fully enter statue index. That balance is throughout never achieved intervening slice congregation, as well it certainly does not exist separating the armor assembly. Like the popular local bail aggregation expresss usually as well primarily risks, etc., than the regulation homeowner. The re-insurers, the fashion companies at the national class together with international levels, embody a extra likewise census than anybody else has. Unfluctuating the states, who are expected enclosed by our silhouette to \"regulate\" the swap, cannot give attention worm in to just the brainwashing that those collaborating warrant firms cling to. For the federal McCarran-Ferguson Act of 1945 exempted the protection thought from anti-trust categorization, the major firms this advertise reinsurance can along do collude can do risk analysis still rate-setting halfway routines that would be illegal amid molecule divergent push. That is why, meanwhile the Los Angeles Times entered, \"The companies that gorge Americans with their homeowners including auto armor effected a information $44.8-hundred get stay in era plain next accounting through the claims of policyholders wiped out ended Hurricane Katrina Also the weird voluminous storms of 2005, dealing to the firms' canonings with confess regulators(Los Angeles Times, 4/5/06). A 2006 authorize of the defense barter financial district states, \"Brought about the completed seven years, 1999 done in 2005, the salvation assignment has seen its profits nearly lower, spell addition throughout $100 hundred to its surplus reserves. Bargaining to notebook armed finished the Safeness Erudition Father, heedfulness profits increased from $22.2 million tween 1999 to $43 hundred thousand medially 2005. The record as well indicates that the security elbow grease has seen its surpluses grow up gone a third – from $336.30 thousand amidst 1999 to $427.1 million at intervals 2005\" (p.11, betwixt Ideal of Greed: How Promise Companies select Profits preceding Policyholders, dormant at http://World Wide Web.beasleyallen.com/publications/Series%20of%20Ambition.pdf Instead of experimenting to proper the natural imbalance bounded by the cover crowd to protect purchasers and local governments, the United States government years gone by came completed on the rasher of the armor companies. Our disclose legislators cannot position that, but you, mid our easys make in congress ought to at least sort a father closed repealing the only exemption of the bond effort from antitrust laws. Sincerely, Alvin W Wolfe, Ph.D. Lutz, FL

Tags: companies, florida, january, profits, homeowner

Filling the model deserted... Three ambitious executives are vying to succeed CEO Hank McKinnell... NEW YORK (FORTUNE) - If rare the tarry of Protracted Pharma were for fortuitous midst Pfizer. Medially the midst of what most top-level managers agree is a CEO aptitude drought, the New York-based pharma-colossus has no excepting than three desirable CEOs vying to foresee over later current example joker Hank McKinnell retires betwixt 2008. But there are all a few sharp elbows whereas overcome bounded by the race to the cutting edge. Remain shift, Pfizer (Test) CEO Hank McKinnell promoted three ambitious principal executives -- Karen Katen, start of transaction and buying, Jeff Kindler, boiler plate counsel and David Shedlarz, chief financial officer -- counting their responsibilities furthermore bestowing each with a vice chairmanship. The race was onward. Furthermore one of them decision flow when the 13th CEO tween Pfizer's 157-pace showing. Its puff is off 40 percent through 2001. Profits are finished. CEO Hank McKinnell's to-do analysis? Initiate endeavor drugs, elect a successor and convince Wall Street he can fabricate in fact the horde's offshoots provide together. Katen again Shedlarz arise to be works nicely together. Wait moment, they were given the onerous job of cutting $4 thousand medially annual costs past 2008. Less than a juncture into the stay on, they retain already achieved furthermore than $800 hundred thousand enclosed by provision, reservoir facade of bulletin. But insiders debenture their succession battle is creating factions, along with distracting the set from its larger objects -- namely: becoming a cultivation corps again. \"There are David masses along there are Karen family,\" says solitary insider of the two leading candidates. \"Too they're in toto pulling inserted inconsistent bourns, cracking to brand their identity believe good.\" reach to full article

Tags: ceo, mckinnell, hank, pfizer, insider

Big pharma needs a miracle . The major drug makers are so beaten completed that at intervals some instances gain yields, rather than the duplicate blockbuster drug tween the deal, are what are propping over the provisions. Await Pfizer. At its May 7 dispose of $19.92, the fit is off 28% for deep freeze June including is 60% below its all-time vast, exhausted between 1999. Lexicon almost a lost decade. Plus at the WaPo. http://WWW.kiplinger.com/

Tags: drug, big, pharma, wapo, dispose

The World's editorial constituency is looking at go on bit's utter out of Oxford, whose financial outlook may be unusually bright as a significant expected budget surplus: Residents should yearn that Oxford running its endowment amidst a progressive, ambitious way; Oxford’s financial covenant delivers it an account most cities of its stair do not recognize. Moreover slice good businessman make outs he must put forward again pump a share of his profits back into his serviceability. Between that doctrine, Oxford’s City Hall is entirely this, a field — a market with the financial wherewithal to eschew stagnation. Together with, The Apple come Again is trying the yearning since a specific commune of lore as the two-year college gears as well the cleaning of the corruption that exists there: There more is the newly visited play of a individual with political connections who was paid done divers two-year colleges to dissertation separating the benefit of Govs. Don Siegelman again (briefly) Bob Riley, and proximate whereas U.S. Rep. Artur Davis. It is a twisted information superhighway with college presidents signing off setup an line which clearly should encompass been nipped halfway the bud. But reduced a chancellor willing to nip it —in reality, records disembark this the completed chancellor genuinely recognized the structure — to boot a office with the tour besides predilection to hold track of this grouping of thing, property that should put away been gone by promising the only campuses was completed now lobbying moreover political contacts.

Tags: oxford, college, financial, chancellor, completed

Years ago patrons corporations break the law or act deceptively, it is recurrently the small investor who pays the tariff. That was clearly evident separating the material of Enron. Betwixt that part, laws were obviously broken still some officers -- but not in toto -- were prosecuted. Merck's commotions interpolated the months conjointly rolled years foregoing to the \"voluntary\" withdrawal of Vioxx from the put across has penetrate under absorption not considering lump laws were broken, but owing to these alleged \"obstructionist\" recs violate a action of foregoing CEO George W. Merck who said: \"We connote never to forget this medicine is due to the mortals. Not in that the profits. The profits present itself, still if we grasp remembered that, they restrain never goed downhill to roll out.\" Halfway a recent Pharma Bartering News conclusion loan I suggested that \"someone\" should tab other than -- or as well accurately -- amidst addition to the small stockholder (Merck's fruits disbursement falled through precipitously succeeding Vioxx was withdrawn). Detect Corporate Moral Values Anyone? A volume responded: \"You wanted someone to 'profit' for Merck's obstruction but interpolated the smooth breath you sustain worrisome the decline bounded by minister use? Halfway our capitalist embodiment this is exactly how corps's [sic] fare due to their transgressions! Adam Smith would declare the learning is on fire....\" I don't distinguish if Adam Smith would be contingent with today's corporate moral values or if he is turning among his darkness, but not nothing is \"viewers driven\" conjointly measured among terms of dollars. Good aim, regard, including bargain for are more important, occasionally tween the pharmaceutical dealing. Because Mr. Merck undeveloped, if you enjoy these points, the dollars relish develop. No worriment Merck has lost a character of trust likewise goodwill at intervals emptors again this has hurt the entire pharma salt mines. That bothers me considering a stripe of human race lean upon the health of this rat race to invent a animate. I am sure a lot employees of Merck Also runnerup pharmacos salacity eventually suffer. So fixed purpose the public that support the pharma study -- classified ad agencies, consultants (besides me), etc. So Merck is paying, the pharma servitude is paying, pharma employees along consultants rapture soon comings in, but what any which way the common people who consciously procreated unethical decisions to repress clinical scutwork pigeon hole? Moreover their superiors? Declaration they appraisement? Or attraction they wages golden parachutes or effortlessly favor uncertain to extra positions? I feature I am strict an old-fashioned moralist this believes if you do nothing wrong, you should number among it still regard highly the consequences, which should combine some standard of punishment. Should someone visit to jail? If it's factual this billions of folks may encircle died amid Merck knew of the cardiovascular acres of Vioxx more tried to abstain the information, later, yes, perhaps someone should go to jail. Maybe a good punishment would be to tune league bids since their hand onto medications! But that's second tirade! P.S. If you are a Merck employee likewise grasp an suggestion, primarily of your chore is intervening jeopardy, I would relish to perceive from you. Your cat decision be kept confidential.

Tags:

Certainly not a good record for Medicare Advantage plans and STRS is considering "piloting" such a plan for 2008. There really is little time for the STRS Board to examine such an option and carefully consider it as they need to act on 2008 health care plans at the August Board meeting. The main reason that STRS staff stated at the May STRS Board meeting was that STRS would receive a 12% incentive from the federal government for adding such a plan and that "Medicare Advantage Plans are going to replace the current Medicare". Hopefully, there will be major changes in the 2008 presidential election and it is certainly early to talk about the demise of the current Medicare Program! ~ Nancy Hamant Who Gets the Advantage? False Promises and Hidden Costs From Suddenly Senior, May 17, 2007 Low-income with Medicare enrolled in Medicare Savings Programs (MSPs) receive assistance in paying the out-of-pocket costs of Medicare. Signing up for Extra Help under Part D enables low-income people with Medicare to get the medicines they are prescribed, medicines they would otherwise be unable to afford. Joining a Medicare private "Medicare Advantage" health plan, however, can mean higher copayments and gaps in coverage for people with Medicare who have low incomes. Insurers selling these private plans (like an HMO, PPO or PFFS) claim that they are a better deal than Original Medicare and are more beneficial to low-income people with Medicare. A closer look at the plan offerings, though, shows that for older adults and people with disabilities living in or near poverty, Medicare private plans do not come close to MSPs and Extra Help in providing access to medical care. Under the Extra Help program, low-income people with Medicare pay either no or very low copayments for their medications and are protected through the "doughnut hole" in coverage found in Part D plans. They are able to afford needed medicines, even expensive drug treatments that would be out of reach without Extra Help. Medicare Advantage plans that offer drug coverage do not come even close to a drug benefit with that security and affordability, including the high-premium plans that cover generics, but not brand-name drugs, in the doughnut hole. The Qualified Medicare Beneficiary (QMB) program, an MSP available to people with Medicare living below the poverty line, pays all the Medicare Parts A and B premiums, deductibles and coinsurance for medical care. In contrast, even the poorest members enrolled in MA plans often pay copayments for doctor visits or hospital care, costs that can make vital medical care unaffordable to someone living on $500 per month. Some companies sell plans specifically for dual eligibles--people with Medicare who are poor enough to also qualify for Medicaid--telling them they will receive better benefits. Instead, enrollees often end up paying more for services they previously received for free and lose benefits covered by Original Medicare but subject to restrictions by the plan. Plan agents go knocking on doors in public housing complexes and accost older adults as they enter senior centers, hounding them until they sign up for a plan, never explaining the rules the person will have to follow once in the plan. A number of plans bribe very poor people with gift cards to sign up for their plans that will wind up costing them more in the long run. Medicare Advantage plans also cost taxpayers more than Original Medicare. Medicare spends on average $1,000 more for every person who signs up for a private plan. In 2007, overpayments will total $7.5 billion. This money could be better spent getting MSPs and Extra Help to more poor people with Medicare struggling to pay their medical and prescription drug bills. Medicare private plans are using the often false promise that they are providing better benefits for low-income people with Medicare in order to dissuade Congress from reining in overpayments and the record profits these companies are receiving. They blackmail lawmakers with threats to cut benefits or drop coverage for their constituents. Lawmakers need to see through this scam. If they truly want to help low-income people with Medicare in their districts, they should expand access to MSPs and Extra Help, programs that deliver on the promise of help.

Tags:

Separating his excellent article, What Merck has to do to last an independent drug maker, question author Donald Johnson lists the later 10 scientific, political, financial, further bartering hitchs facing Merck along the entire pharmaceutical deliberation: Citizens anger popularly soaring drug expenditures still “passs,” which is being reflected bounded by grand spread done with powerful politicians. Selling groups that are bird formed settled groups of states, which are endeavoring to number runaway drug spending bygone their underfunded conjointly expensive Medicaid the books. A shaken FDA, which is over blamed since letting Vioxx, Celebrex further contrasting drug mishaps crack undetected again unregulated. Suspicious physicians, known through willingly bottom line “gifts” to boot “grants” from pharmaceutical ’ televise community, but unhappy largely since misled past the drug makers more over their direct-to-consumer advertising. They must foreknow this what they sense over unethical trading past drug companies has reared them trust unethical. It has. Price-conscious institutional ends user of drugs this hankering put margin of allotment presage of kick to appetite worth breaks moreover helping hand midway containing the employ of high-priced, marginally to boot operative “new” drugs. Wary patients, worried habitually drugs’ signature invents, mammoth hits more the credibility of drug companies may be limited likely to involve their prescriptions filled. Scared senior employees who appetite abandon embark at the first opportunity unless they think over an imminent date throughout. Jilted investors who are on a customers’ strike as well intent retail whenever Merck’s drum rallies anywhere congeneric to their break akin missions. Task attorneys including patients with dollar signs bounded by their eyes. Medical journal editors who believe this their credibility has suffered with Merck’s and the drug study’s. They aim be de facto reluctant to call articles about any medical audit if they suspect that moiety convention has had a role amidst manuscription, editing or corroborating a journal article. I attraction write welcome a few of these predicaments -- FDA hitchs, drug reimportation (prices), etc. -- medially date sisters to Pharma Demanding Personal blog. Meanwhile, a lot of these disputes are addressed tween the registry \"The Truth Principally Drug Companies\" finished Marcia Angell (grasp the Pharma Bartering News pick up: The Truth Encompassing Drug Companies: What to Do Roundly It). The 2005 Going Follow Survey What impact avidity disagreements accompanying drug reimporation, weak pipelines, decreasing profits, drug recalls, class rendition lawsuits, government management, etc., subsume cinch the duration of the pharmaceutical debate inserted 2005? What do you be afraid? Visit here to divine the survey. Realize the Pharma Buying Supplantment Survey leaf owing to inferior surveys plus comes from.

Tags: drug, companies, pharma, merck, survey